Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00788398
Other study ID # GHS-03-08-06
Secondary ID W81XWH-08-1-0473
Status Completed
Phase N/A
First received November 7, 2008
Last updated February 10, 2016
Start date June 2009
Est. completion date April 2015

Study information

Verified date February 2016
Source Greenville Health System
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardCanada: Ethics Review Committee
Study type Interventional

Clinical Trial Summary

Open fracture wounds are a constant challenge to orthopaedic surgeons, with infections a common complication. There is currently little evidence as to which is the most effective way to wash out these wounds. This study is a multi-center, prospective, randomized study. The infection rates will be compared between irrigation using high pressure versus low pressure versus gravity flow, and also saline versus a soap solution as the irrigation solution. The results from this study will help to determine the best method of washing out open fractures wounds. In this study, all open wounds will be washed out using methods commonly used by orthopaedic surgeons


Recruitment information / eligibility

Status Completed
Enrollment 2540
Est. completion date April 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender Both
Age group 14 Years to 85 Years
Eligibility Inclusion Criteria:

1. Men or women who are skeletally mature.

2. Fracture of any extremity with complete radiographs.

3. Open fractures (Gustilo-Anderson Types I-IIIB) (Table 2)*.

4. Fracture requiring operative fixation.

5. Provision of informed consent.

Exclusion Criteria:

1. Open fractures with an associated vascular deficit (Gustilo-Anderson Type IIIC).

2. Known allergy to detergents or castile soap ingredients.

3. Previous wound infection or history of osteomyelitis in the injured extremity.

4. Previous fracture with retained hardware in injured extremity that will interfere with new implant fixation.

5. Surgical delay to operative wound management greater than 24 hours from hospital admission.

6. Use of immunosuppressive medication within 6 months.

7. Immunological deficient disease conditions (e.g. HIV).

8. Fracture of the hand (metacarpals and phalanges).

9. Fracture of the toes (phalanges).

10. Likely problems, in the judgment of the investigators, with maintaining follow-up. We will, for example, exclude patients with no fixed address, those who report a plan to move out of town in the next year, or intellectually challenged patients without adequate family support.

11. Previous randomization in this study or a competing study.

Study Design

Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
Saline Solution
Irrigation with Saline
Soap solution
Irrigation with Castile Soap Solution (80 ml per 3L bag of saline)
Gravity Flow Irrigation
Gravity flow irrigation will be standardized across participating centers as 3L bags of normal saline (alone or with soap solution) suspended 6-8 feet above floor level using an I.V. pole. Irrigation tubing (measuring 1/4 - 3/8 inch inner diameter) will be connected to the 3L bag and secured with a stopcock (or compressive device) until ready for use.
Low Pressure Irrigation
Irrigation with the Stryker SurgiLav System. At the low pressure setting delivers 5.9 p.s.i. pressure. The high-flow irrigator tip will be held perpendicular to and 5cm above the wound. Irrigation with the Zimmer PulsaVac. For low pressure delivery, the shower tip will be used at the low pressure setting which delivers a pressure of 5.8 p.s.i.
High Pressure
Irrigation with the Stryker SurgiLav System. For the high pressure delivery, the multi-orifice tip will be used at the high setting which delivers a pressure of 30 p.s.i. Irrigation with the Zimmer PulsaVac System: For the high pressure delivery the shower tip will be used at the high pressure setting which delivers a pressure of 23 p.s.i.

Locations

Country Name City State
Australia The Alfred Prahran
Canada Queen Elizabeth II Health Sciences Center Halifax Nova Scotia
Canada Hamilton Health Sciences Hamilton Ontario
Canada McMaster University Hamilton Ontario
Canada London Health Sciences London Ontario
Canada Hospital du Sacre-Coeur de Montreal Montreal Quebec
Canada McGill University Health Centre Montreal Quebec
Canada Royal Columbian Hospital-New Wesminster New Westminster British Columbia
Canada Ottawa Hospital- Civic Ottawa Ontario
Canada Hôpital de l'Enfant-Jésus Quebec
Canada Université de Sherbrooke Sherbrooke Quebec
Canada St. Michael's Hospital Toronto Ontario
Canada Sunnybrook Health Sciences Centre Toronto Ontario
Canada Vancouver General Hospital Vancouver British Columbia
Canada Health Sciences Winnipeg Winnipeg Manitoba
India Sancheti Institute Prune
Norway Ulleval University Hospital Oslo
United States Univeristy of Alabama at Birmingham Birmingham Alabama
United States Lahey Clinic Burlington Massachusetts
United States University of Missouri Health Care Columbia Missouri
United States Miami Valley Hospital/Wright State University Dayton Ohio
United States Duke University Durham North Carolina
United States Brooke Army Medical Center Fort Sam Houston Texas
United States Orthopaedic Associates of Michigan Grand Rapids Michigan
United States Greenville Hospital System Greenville South Carolina
United States Wishard Health Services, Indiana University Indianapolis Indiana
United States Hennepin County Medical Center Minneapolis Minnesota
United States University of California-Irvine Orange California
United States University of Pittsburg Pittsburg Pennsylvania
United States University of California- San Francisco San Francisco California
United States St. Louis University St. Louis Missouri

Sponsors (3)

Lead Sponsor Collaborator
Greenville Health System McMaster University, United States Department of Defense

Countries where clinical trial is conducted

United States,  Australia,  Canada,  India,  Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Re-operation within 12 months post initial surgery to treat an infection, manage a wound healing problem, or promote fracture healing. within 12 months No
Secondary Patient function and quality of life measured by the Short Form-12 (SF-12) and the EuroQol-5D 12 months No